Nikhil Thaker, MD
Radiation Oncology · Pennington, NJNPI 1861782641
Payments from drug & device makers
What this record shows
16 manufacturers reported payments, led by Histosonics, Inc. at 52.4% of the total. 2025 is the largest year on record at $1,316, 8.8 times the $150 reported in 2019.
Across 44 payments — averaging $44.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Histosonics, Inc.$1K
- Telix Pharmaceuticals$151
- Galvanize Therapeutics, Inc$134
- Merck$122
- Amgen$114
- Incyte Corporation$78
- plus $339 from 10 others
What the payments were for
- Travel & lodging$96249%
- Food & beverage$1,00551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Histosonics, Inc. | 2 | $1,031 |
| Telix Pharmaceuticals | 2 | $151 |
| Galvanize Therapeutics, Inc | 1 | $134 |
| Merck | 7 | $122 |
| Amgen | 8 | $114 |
| Incyte Corporation | 5 | $78 |
| AstraZeneca | 5 | $73 |
| Siemens Medical Solutions USA, Inc. | 2 | $63 |
| Myovant Sciences Inc. | 4 | $62 |
| Accuray Incorporated | 1 | $28 |
| Seagen Inc. | 2 | $27 |
| Secura Bio, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| GSK | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$134
How this compares
$1,968 in reported general payments places this provider in the 75th percentile of 132 radiation oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 13 | $397 |
| Pentoxifylline | 11 | $258 |
| Dexamethasone | 21 | $216 |
| Mometasone Furoate | 16 | $126 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Pennington
- Timothy ChenPennington$43K
- Michael GreenbergCherry Hill$335K
- Glen GejermanHackensack$180K
- Marc RudoltzWest Orange$166K
- Salma JabbourNew Brunswick$163K
- Edward SoffenMonroe Twp$50K
- Adnan DanishWayne$45K
- Brett LewisHackensack$23K
- Sang SimLong Branch$16K
- Thomas KoleMiddletown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.